Neonmind Biosciences Stock Cash Flow From Operations
| NMDBFDelisted Stock | USD 0.50 0.00 0.00% |
NeonMind Biosciences fundamentals help investors to digest information that contributes to NeonMind Biosciences' financial success or failures. It also enables traders to predict the movement of NeonMind Pink Sheet. The fundamental analysis module provides a way to measure NeonMind Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeonMind Biosciences pink sheet.
NeonMind |
NeonMind Biosciences Company Cash Flow From Operations Analysis
NeonMind Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current NeonMind Biosciences Cash Flow From Operations | (5.82 M) |
Most of NeonMind Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeonMind Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, NeonMind Biosciences has (5.82 Million) in Cash Flow From Operations. This is 101.1% lower than that of the Healthcare sector and 109.31% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.6% higher than that of the company.
NeonMind Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeonMind Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of NeonMind Biosciences could also be used in its relative valuation, which is a method of valuing NeonMind Biosciences by comparing valuation metrics of similar companies.NeonMind Biosciences is currently under evaluation in cash flow from operations category among its peers.
NeonMind Fundamentals
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 | |||
| Operating Margin | 735.17 % | |||
| Current Valuation | 799.08 K | |||
| Shares Outstanding | 35.82 M | |||
| Price To Book | 12.19 X | |||
| Price To Sales | 18.10 X | |||
| Gross Profit | (84.45 K) | |||
| EBITDA | (6.65 M) | |||
| Net Income | (7.21 M) | |||
| Cash And Equivalents | 89.22 K | |||
| Total Debt | 450.01 K | |||
| Debt To Equity | 1.58 % | |||
| Current Ratio | 0.59 X | |||
| Book Value Per Share | (1.22) X | |||
| Cash Flow From Operations | (5.82 M) | |||
| Earnings Per Share | (0.14) X | |||
| Beta | -1.12 | |||
| Market Capitalization | 272.23 K | |||
| Total Asset | 1.34 M | |||
| Z Score | -13.2 | |||
| Net Asset | 1.34 M |
About NeonMind Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeonMind Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeonMind Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeonMind Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in NeonMind Pink Sheet
If you are still planning to invest in NeonMind Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeonMind Biosciences' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |